(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 November 2014 (06.11.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/178820 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *C07K 14/00* (2006.01)

(21) International Application Number:
PCT/US2013/038659

(22) International Filing Date:
29 April 2013 (29.04.2013)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant: **TEVA PHARMACEUTICALS AUSTRALIA PTY LTD.** [—/AU]; Level 2, 37 Epping Road, Macquarie Park, NSW, 2113 (AU).

(72) Inventors; and
(71) Applicants : **CLARKE, Adam** [AU/AU]; Level 2, 37 Epping Road, Macquarie Park, NSW 2113 (AU). **POLLARD, Matthew** [AU/AU]; Level 2, 37 Epping Road, Macquarie Park, NSW 2113 (AU). **DOYLE, Anthony, Gerard** [AU/AU]; Level 2, 37 Epping Road, Macquarie Park, NSW 2113 (AT). **BEHRENS, Collette** [AU/AU]; Level 2, 37 Epping Road, Macquarie Park, NSW 2113 (AU). **YAMAGISHI, Tetsuo** [JP/AU]; Level 2, 37 Epping Road, Macquarie Park, NSW 2113 (AU). **WILSON, David, S. Jr.** [US/US]; 735 Galveston Drive, Redwood City, CA 94063 (US). **POGUE, Sarah, L.** [US/US]; 5471 Midday Common, Freemont, CA 94555 (US). **TAURA, Tetsuya** [JP/US]; 514 Driscoll Place, Palo Alto, CA 94306 (US).

(74) Agents: **COCCA, Brian A.** et al.; Stradley Ronon Stevens & Young, LLP, 30 Valley Stream Parkway, Malvern, PA 19355 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

[Continued on next page]

(54) Title: ANTI-CD38 ANTIBODIES AND FUSIONS TO ATTENUATED INTERFERON ALPHA-2B




FIG. 1

(57) Abstract: Antibodies that specifically bind to CD38, as well as constructs comprising such antibodies fused to attenuated interferon alpha-2B proteins are provided. Anti-CD38-attenuated interferon alpha-2b fusion constructs may be used to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, as well as to induce apoptosis in such cells. Inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.

WO 2014/178820 A1

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*